Workflow
Praluent (alirocumab)
icon
Search documents
Regeneron (REGN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
ZACKS· 2025-08-01 14:30
Core Insights - Regeneron reported $3.68 billion in revenue for Q2 2025, a year-over-year increase of 3.6%, with an EPS of $12.89 compared to $11.56 a year ago, exceeding Zacks Consensus Estimates for both revenue and EPS [1] Revenue Performance - Eylea (Aflibercept) in the US generated $1.15 billion, surpassing the average estimate of $1.03 billion, but reflecting a year-over-year decline of 25.2% [4] - Praluent (alirocumab) in the US reported revenues of $65.8 million, exceeding the average estimate of $54.57 million, with a year-over-year increase of 17.3% [4] - Total net product sales amounted to $1.63 billion, compared to the average estimate of $1.46 billion, representing a year-over-year decline of 15% [4] - Collaboration revenues totaled $1.86 billion, exceeding the average estimate of $1.73 billion, with a year-over-year increase of 22.1% [4] - Total Bayer collaboration revenue was $415 million, surpassing the estimate of $388.54 million, reflecting a year-over-year increase of 10.6% [4] - Total Sanofi collaboration revenue reached $1.44 billion, exceeding the average estimate of $1.36 billion, with a year-over-year increase of 26% [4] Stock Performance - Regeneron's shares returned -0.4% over the past month, while the Zacks S&P 500 composite increased by 2.3%, indicating potential underperformance in the near term [3]
Unlocking Q2 Potential of Regeneron (REGN): Exploring Wall Street Estimates for Key Metrics
ZACKS· 2025-07-29 14:16
Core Viewpoint - Analysts forecast Regeneron (REGN) will report quarterly earnings of $8.03 per share, reflecting a year-over-year decline of 30.5%, with anticipated revenues of $3.34 billion, a decrease of 5.7% compared to the previous year [1]. Earnings Estimates - The consensus EPS estimate has been revised downward by 6.5% over the past 30 days, indicating a collective reassessment by analysts [2]. - Revisions to earnings estimates are crucial indicators for predicting investor actions regarding the stock, with empirical research showing a strong correlation between earnings estimate trends and short-term stock price performance [3]. Revenue Forecasts - Analysts predict 'Revenues- Other Revenue' at $125.38 million, a year-over-year increase of 20% [5]. - 'Revenues- Net product sales' are expected to reach $1.46 billion, reflecting a decline of 23.9% year-over-year [5]. - 'Total Bayer collaboration revenue' is projected at $388.54 million, indicating a year-over-year increase of 3.6% [5]. - The consensus estimate for 'Revenues- Collaboration' stands at $1.73 billion, a year-over-year increase of 13.7% [6]. - 'Revenues- Eylea (Aflibercept)- US' are expected to be $1.03 billion, down 33% from the prior year [6]. - 'Revenues- Praluent (alirocumab)- US' are forecasted at $54.57 million, a decrease of 2.7% year-over-year [6]. Product-Specific Revenue Insights - 'Revenues- Libtayo- US' are estimated to reach $234.04 million, reflecting a year-over-year increase of 28.3% [7]. - 'Revenues- Evkeeza- US' are expected at $36.84 million, indicating an 18.8% year-over-year increase [7]. - 'Revenues- Dupixent (dupilumab)- ROW' are projected at $1.16 billion, a year-over-year increase of 22.7% [8]. - 'Revenues- Dupixent (dupilumab)- US' are expected to reach $3.05 billion, reflecting a year-over-year increase of 16.7% [8]. - 'Revenues- Kevzara (sarilumab)- ROW' are estimated at $47.83 million, indicating a year-over-year increase of 7.2% [9]. Market Performance - Over the past month, shares of Regeneron have returned +6.4%, outperforming the Zacks S&P 500 composite's +3.6% change [9].
Regeneron Prevails over Amgen in Antitrust PCSK9 Lawsuit Protecting Biotech Innovation and Patient Access to Life-Saving Treatments
Globenewswire· 2025-05-15 18:02
Core Viewpoint - A federal court jury found Amgen liable for antitrust violations, awarding Regeneron $135.6 million in compensatory damages and $271.2 million in punitive damages due to Amgen's anticompetitive practices that hindered competition for Praluent [1][3]. Summary by Relevant Sections Antitrust Violations - Amgen was found to have violated multiple laws, including the Clayton Act and Sherman Act, by using cross-therapeutic bundled rebates to favor Repatha over Praluent, thereby preventing fair competition [1][2]. Jury Verdict and Damages - The jury awarded Regeneron a total of $406.8 million, comprising $135.6 million in compensatory damages and $271.2 million in punitive damages aimed at deterring similar future conduct [3]. Company Statements - Regeneron emphasized the importance of fair competition in the biotech industry, stating that anticompetitive tactics undermine patient access to innovative therapies and hinder medical advancements [4]. Product Information - Praluent, developed by Regeneron and Sanofi, is designed to lower LDL cholesterol levels by inhibiting PCSK9, and is approved in 60 countries [6][7]. Technology and Innovation - Regeneron's proprietary VelocImmune technology has been instrumental in developing fully human monoclonal antibodies, contributing to a significant portion of FDA-approved treatments [8][9].
What Analyst Projections for Key Metrics Reveal About Regeneron (REGN) Q1 Earnings
ZACKS· 2025-04-24 14:21
Core Viewpoint - Analysts expect Regeneron to report quarterly earnings of $8.76 per share, reflecting a year-over-year decline of 8.3%, with revenues projected at $3.25 billion, an increase of 3.3% from the previous year [1]. Earnings Estimates - The consensus EPS estimate has been revised 6.1% lower in the last 30 days, indicating a collective reevaluation by analysts [1][2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock performance [2]. Revenue Projections - Analysts predict 'Revenues- Other Revenue' to reach $132.13 million, a 13% increase year-over-year [4]. - 'Revenues- Net product sales' are expected to be $1.62 billion, indicating a decline of 8.2% from the previous year [4]. - 'Total Bayer collaboration revenue' is projected at $374.73 million, reflecting a 5.3% year-over-year increase [4]. - The consensus estimate for 'Revenues- Collaboration' stands at $1.49 billion, a 17.9% increase from the year-ago quarter [5]. Product-Specific Revenue Estimates - 'Revenues- Praluent (alirocumab)- US' are expected to be $57.71 million, down 17.6% year-over-year [5]. - 'Revenues- Eylea (Aflibercept)- US' are projected at $1.19 billion, indicating a decline of 15.2% [5]. - 'Revenues- Evkeeza- US' are estimated at $32.40 million, a 35% increase year-over-year [6]. - 'Revenues- Libtayo- ROW' are expected to reach $127.95 million, reflecting a 22.2% increase [6]. - 'Revenues- Libtayo- US' are projected at $214.99 million, indicating a 35% year-over-year increase [6]. - 'Revenues- Dupixent (dupilumab)- ROW' are expected to be $1.08 billion, a 25.7% increase [7]. - 'Revenues- Kevzara (sarilumab)- ROW' are projected at $41.91 million, down 5% year-over-year [7]. - 'Revenues- Kevzara (sarilumab)- US' are expected to reach $52.50 million, indicating a 5% increase [7]. Stock Performance - Over the past month, Regeneron shares have declined by 8.2%, compared to a 5.1% decline in the Zacks S&P 500 composite [8]. - Based on its Zacks Rank 4 (Sell), Regeneron is expected to underperform the overall market in the upcoming period [8].